BFL-1 deletion did not increase the spontaneous death of these melanoma cells (Supplementary Fig. 4b), nor their sensitivity to single-agent treatment with any of the BH3-mimetic drugs tested or PLX4032, when used as single agents (Fig. 1a–d). This evidence concerns the gene BCL2A1 and melanoma.